Long-term management of patients with differentiated thyroid cancer (DTC) commonly includes TSH-suppressive therapy with L-T4 and, in case of postsurgical hypoparathyroidism, Calcium-D3 supplementation, both of which may affect skeletal health. Experience with female patients treated for DTC at a young age and who were then receiving long-term therapy with L-T4 and Calcium-D3 medication is very limited to date. This cross-sectional study set out to investigate effects of Calcium-D3 supplementation and TSH-suppressive therapy on bone mineral density (BMD) in 124 young female patients treated for DTC at a mean age of 14 years and followed-up for an average of 10 years. BMD was found to be significantly higher in patients receiving Calcium-D3 medication than in patients not taking supplements. The level of ionized calcium was the strongest factor determining lumbar spine BMD in patients not receiving Calcium-D3 supplementation. Pregnancy ending in childbirth and HDL-cholesterol were associated with a weak adverse effect on spine and femoral BMD. No evidence of adverse effects of L-T4 and of radioiodine therapies on BMD was found. We conclude that Calcium-D3 medication has a beneficial effect on BMD, and that TSH-suppressive therapy does not affect BMD in women treated for DTC at young age, at least after 10 years of follow-up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1507/endocrj.EJ14-0408 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Change in pericardial fat volume in postmenopausal women with papillary thyroid cancer undergoing thyrotropin suppressive therapy.
BMC Endocr Disord
January 2025
Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
Background: Despite TSH suppressive therapy improve the prognosis for the patient with differentiated thyroid cancer (DTC), there is an increasing concern regarding the potentially harmful effects of lifelong TSH suppression. Therefore, we aimed to examine the changes in body composition under TSH suppression in postmenopausal women with DTC.
Methods: The body composition was assessed by the volumes as following; fat tissues of the epicardium and abdominal visceral and subcutaneous areas; bilateral psoas muscle or thigh muscle.
Short-Term Postoperative Depression and Anxiety in Patients with Differentiated Thyroid Carcinoma: Assessment of Potential Oncologic-Psycho Relevance.
Int J Endocrinol
October 2024
Shandong University, Cheeloo College of Medicine, Jinan, Shandong, China.
Article Synopsis
- The study aimed to explore the impact of TSH suppressive therapy on short-term depression and anxiety in patients with differentiated thyroid cancer (DTC) post-surgery.
- Conducted with 831 patients, the research found significant reductions in anxiety and depression levels three months after surgery, with various factors like educational background and tumor characteristics being influential.
- It concluded that TSH suppression therapy plays a crucial role in alleviating cancer-related anxiety and depression, with lower TSH levels correlating with worsening anxiety and depression scores.
Impact of Hashimoto's thyroiditis on the tumor microenvironment in papillary thyroid cancer: insights from single-cell analysis.
Front Endocrinol (Lausanne)
October 2024
Department of Pharmacogenomics, College of Bioinformatics and Science Technology, Harbin Medical University, Harbin, China.
Article Synopsis
- This study analyzes the effects of Hashimoto's thyroiditis (HT) on the microenvironment of papillary thyroid cancer (PTC) using extensive single-cell data from 11 patients.
- It highlights specific cell populations related to HT that create a thyroid-stimulating hormone (TSH)-suppressive environment and promote immune interactions, crucial for personalized medicine approaches.
- The research also introduces a new method for analyzing RNA-seq data, enhancing the understanding of the relationship between autoimmunity and cancer, and potentially revealing new therapeutic targets for PTC.
No Correlation between PD-L1 and NIS Expression in Lymph Node Metastatic Papillary Thyroid Carcinoma.
Diagnostics (Basel)
August 2024
Department of Internal Medicine and Clinical Oncology, Semmelweis University, 1124 Budapest, Hungary.
Approximately 90% of thyroid cancers are differentiated thyroid cancers (DTCs), originating from follicular epithelial cells. Out of these, 90% are papillary thyroid cancer (PTC), and 10% are follicular thyroid cancer (FTC). The standard care procedure for PTC includes surgery, followed by radioiodine (RAI) ablation and thyroid-stimulating hormone (TSH) suppressive therapy.
View Article and Find Full Text PDFThyroid hormones for euthyroid patients with simple goiter growing over time: a survey of European thyroid specialists.
Endocrine
August 2024
Department of Endocrinology, Odense University Hospital, Odense, Denmark.
Article Synopsis
- An online survey of European thyroid specialists revealed that 28% believe thyroid hormone (TH) treatment may be appropriate for euthyroid patients with growing simple goiters, despite guidelines against this practice.
- There were significant regional differences in support for TH treatment, with only 7% in The Netherlands compared to 78% in the Czech Republic.
- Factors influencing the likelihood of recommending TH included the specialist's age and the historical iodine insufficiency of their region, while gender, country, and economic factors showed weak associations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!